MHRA Compliance Regulations
BioPlex Peptides UK

The MHRA regulates medicines and medical devices in the UK and provides public services for reporting or checking suspicious online sellers of medicines and medical devices.

The MHRA has also published public guidance around GLP-1 medicines and has warned that prescription-only medicines should only be obtained from legitimate pharmacies with a valid prescription issued by a healthcare professional.

BioPlex Peptides will continue to monitor MHRA guidance, product classification issues, and wider regulatory developments affecting online research supply.

BioPlex Peptides is currently reviewing changes across the UK research peptide market following increased regulatory attention from the MHRA around the online sale of unauthorised medicinal products, prescription-only medicines, GLP-1 products, and other compounds that may fall under medicinal product classification.

The MHRA has made clear that selling fake, unsafe, unauthorised, or illegally supplied medicines online can have serious consequences and may be unlawful. The MHRA also operates reporting and checking services for suspicious online sellers and maintains a “Not Recommended” list for websites known for selling medicines illegally.

Recent MHRA activity has included enforcement action involving unlicensed weight loss medicines, including tirzepatide and retatrutide, as well as other peptide products. The MHRA has also stated that its Criminal Enforcement Unit works to disrupt illegal medicine supply chains, remove unsafe or unauthorised products, and bring prosecutions where appropriate.

As part of this changing regulatory environment, BioPlex Peptides has removed GLP-1 related products and other products identified for review. The MHRA Borderline Medicines team may review products individually to assess whether they fall within the definition of a medicinal product under the Human Medicines Regulations 2012. This means that the classification of a product is not decided only by how it is labelled, but also by its composition, presentation, intended purpose, claims, and how it is supplied.

BioPlex Peptides understands that some UK peptide websites are now being contacted and asked to remove certain products within a set timeframe, before further enforcement action is considered. This appears to be part of a wider compliance shift within the UK peptide market, with websites gradually removing products one by one as regulatory reviews continue.

Products currently under review or removed from public sale include, but may not be limited to:

Tirzepatide
Cagrilintide
Retatrutide
Semax
Selank
Gonadorelin
Hexarelin
Tesamorelin
Sermorelin
Melanotan 1
Melanotan 2
Melatonin
Kisspeptin
Mazdutide
Thymalin
Epitalon

BioPlex Peptides is treating this matter seriously and is reviewing product listings, product descriptions, website wording, customer-facing information, marketing content, and research-only disclaimers. Our aim is to remain aligned with UK regulatory expectations and to ensure that products are not presented in a way that could be interpreted as medicinal, therapeutic, diagnostic, cosmetic, dietary, weight-loss, or personal-use supply.

This page will be updated weekly as the situation develops and as further compliance reviews are completed.

For official MHRA information, visit the Medicines and Healthcare products Regulatory Agency on GOV.UK:
https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

You can also check or report suspicious online medicine sellers through the MHRA service here:
https://report-or-check-suspicious-activity.mhra.gov.uk/check

Read our full BioPlex Peptides MHRA Compliance Statement here:
UK Peptide Compliance and BioPlex Product Review – BioPlexPeptides.co.uk